WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific Sessions in Chicago, Illinois from November 6-9, 2026. Key Facts A late-breaking oral presentation will feature data from an exploratory post-hoc analysis of the Phase 3 OCEANIC-STROKE study, which evaluated asundexian versus placebo, both in combination with antiplatelet therapy, in patients after
See full post here as originally published on this site
